BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
路透社2026/10/09 15:12Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Latest Updates
October 9 - ** Definium Therapeutics (DFTX.O) shares rose 7.4%, to $36.7
** If the rally holds, the stock is on track for its biggest one-day gain since June
** JPMorgan initiated coverage on the stock with an "Overweight" rating and a target price of $84
** The brokerage said Definium’s leading candidate drug DT120 ODT could transform the treatment of neuropsychiatric disorders
** Based on current data, the firm considers DT120 ODT (an LSD oral formulation for major depressive disorder and generalized anxiety disorder) a "de-risked asset"
** The new target price represents 145.7% upside from the latest closing price
** "Although changes in the macro environment may pose potential risks to investment in the sector, we believe the positives for Definium outweigh the negatives," the brokerage said
** A period of "frequent milestone events" is expected going forward, including the planned FDA approval submission in the first half of 2027
** The brokerage expects total DT120 orally disintegrating tablet (ODT) sales to approach $5 billion by 2035
**Including intraday swings, the stock has more than doubled year to date
(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or may not include necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by use of automated translation functionality.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Needham raises CrowdStrike target price to $310
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
